Journal
FRONTIERS IN NEUROSCIENCE
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2018.00520
Keywords
Alzheimer's disease; memory; caffeine; adenosine; adenosine receptors
Categories
Funding
- France Alzheimer
- Fondation de France
- FHU VasCog research network
- programmes d'Investissements d'Avenir LabEx (excellence laboratory) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease)
- ANR
- Fondation pour la Recherche Medicale
- LECMA/Alzheimer Forschung Initiative
- Fondation Plan Alzheimer
- Inserm
- CNRS
- Universite Lille 2
- Lille Metropole Communaute Urbaine
- Region Nord/Pas-de-Calais
- FEDER
- DN2M
- FUI MEDIALZ
- Italian Society of Pharmacology (SIF)
- LabEx DISTALZ
- ANR ADORATAU
- University of Lille
- Region Hauts de France (COGNADORA)
- Fondation pour la Recherche Medicale [SPF20160936000]
Ask authors/readers for more resources
Alzheimer's disease (AD) is the most common neurodegenerative disorder in elderly people. AD is characterized by a progressive cognitive decline and it is neuropathologically defined by two hallmarks: extracellular deposits of aggregated beta-amyloid (A beta) peptides and intraneuronal fibrillar aggregates of hyper- and abnormally phosphorylated Tau proteins. AD results from multiple genetic and environmental risk factors. Epidemiological studies reported beneficial effects of caffeine, a non-selective adenosine receptors antagonist. In the present review, we discuss the impact of caffeine and of adenosinergic system modulation on AD, in terms of pathology and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
